CClinicalTrials.gg
Status unknownNCT02873793SEMINOMESUpdated Aug 22, 2016

Analysis of Transposon Control Pathways in Germinal Cancers of the Testicle

An observational study in Germinal Cancers of the Testicle, sponsored by Centre Hospitalier Universitaire Dijon. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-22.

Sponsored by Centre Hospitalier Universitaire Dijon · Observational

The sponsor has not verified this record recently (last verified Jul 2016), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
15
Ages
18 Years and older
Sex
All
01

Study summary

By analogy with the mouse, the activity of control pathways for transposable elements (TE) in foetal primordial germinal cells could prove to be a determinant for fertility in adulthood in humans. Moreover, defects in the control of transposable elements (TE) could also contribute to the aetiology of germinal testicular cancer, by inducing chromosomal instability and tumorigenesis. In this context, the aim is to analyse a specific type of adult germinal testicular cancers, seminomas. Directly related to our research interest, the histological, transcriptomic and epigenetic features of theses adult tumours are reminiscent of germinal cells normally present in foetuses. The investigator postulates that these similarities could also extend to the biology of transposable elements (TE), and in particular to the initiation of the control of these elements. The management of seminomas requires surgery, orchiectomy, which consists of the total excision of the affected testicles. Using high-resolution high-throughput sequencing techniques, we propose to analyse the control pathways of transposable elements (TE) in tumour samples harvested from surgical pieces in comparison with adjacent healthy tissue. The results obtained in these tumour samples will be compared with those in normal foetal gonad samples.

02

Conditions studied

  • Germinal Cancers of the Testicle
03

In context

Lead sponsor

Centre Hospitalier Universitaire Dijon is the lead sponsor of 495 studies on the registry; 105 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

men with germinal testicular cancer

Inclusion criteria

  • men who have provided oral consent
  • men with germinal testicular cancer with negative or low serum markers (Alpha Foeto Protein AFP and Human Chorionic Gonadotrophin hCG), indicators of a seminomatous-type tumour
  • men who have undergone orchiectomy (total excision of the affected testicle)
  • confirmation of the diagnosis of seminomatous or non-seminomatous type by histology of the surgical piece
  • absence of hepatitis B or C or infection with human immunodeficiency virus (HIV).

Exclusion criteria

Exclusion Criteria:

  • men without national health insurance cover
  • Adults under guardianship
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
15 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • 7/8 cases pure seminomas

    Genetic: Extraction of total RNA from healthy and tumour tissues

  • 5 cases of non-seminoma

    Genetic: Extraction of total RNA from healthy and tumour tissues

  • 3 cases of composite tumours seminoma/non-seminoma.

    Genetic: Extraction of total RNA from healthy and tumour tissues

Interventions

  • GeneticExtraction of total RNA from healthy and tumour tissues
06

What researchers measure

Primary outcomes

  1. The role of Transposable Element in tumorigenesis seminomas adults

    Transcriptomic analysis of adult seminomas

    Time frame: through the study completion up to 36 months

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02873793
Lead sponsor
Centre Hospitalier Universitaire Dijon
Responsible party
Sponsor
First posted
Aug 22, 2016
Start date
Apr 2015
Primary completion
Apr 2018 (estimated)
Last update
Aug 22, 2016

Study contacts

Patricia FAUQUE
Contact
Patricia.fauque@chu-dijon.fr
03.80.29.50. 31 ext. +33
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion